Mucositis: Current management and investigations

Seminars in Radiation Oncology

Volumn 13, Issue 3, 2003, Pages 267-273

  Garden, Adam S ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b Box 97 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; AMPHOTERICIN B; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; BENZYDAMINE; CHLORHEXIDINE; CYTOKINE; GROWTH FACTOR; MISOPROSTOL; POLYMYXIN B; PROSTAGLANDIN; PROSTAGLANDIN E2; TOBRAMYCIN;

ALGORITHM; CANCER RADIOTHERAPY; CELL PROTECTION; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG FORMULATION; HEAD AND NECK CANCER; HUMAN; INCIDENCE; LOZENGE; MUCOSA INFLAMMATION; PATHOGENESIS; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; RADIATION INJURY;

EID: 0042026905     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-4296(03)00028-6     Document Type: Conference Paper

References (37)

1. Vokes E, Haraf D, Kies M: The use of concurrent chemotherapy and radiotherapy for locoregionally advanced head and neck cancer. Semin Oncol 27:34-38, 2000
2. Parsons J, Bova F, Million R: A re-evaluation of split-course technique for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 6:1645-1652, 1980
3. Fu K, Pajak T, Trotti A, et al: A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas. First report of RTOG 9003. Int J Radiat Oncol Biol Phys 48:7-16, 2000
4. Calais G, Alfonsi M, Bardet E, et al: Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 91:2081-2086, 1999
5. Chambers M, Toth B, Martin J, et al: Oral and dental management of the cancer patient: Prevention and treatment of complications. Support Care Cancer 3:168-175, 1995
6. Capizzi R: Amifostine: The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Semin Oncol 23:2-16, 1996
7. Lindegaard J, Grau C: Has the outlook improved for arnifostine as a clinical radioprotector? Radiother Oncol 57:113-118, 2000
8. Brizel DM, Wasserman TH, Henke M, et al: Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18:3339-3345, 2000
9. Bourhis J, De Crevoisier R, Abdulkarim B, et al: A randomized study of very accelerated radiotherapy with an with amifostine in head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 46:1105-1108, 2000
10. Buntzel J, Schuth J, Kuttner K, et al: Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Support Care Cancer 6:155-160, 1998
11. Abitbol A, Lewin A, Rodrigues M, et al: Sequential trials of concurrent hyperfractionated radiation therapy and 5-fluorouracil, cisplatin and paclitaxel with and without amifostine in patients with locally advanced head and neck squamous cell carcinoma. Proc ASCO 20:228a, 2001 (abstr)
12. Epstein JB, Gorsky M, Guglietta A, et al: The correlation between epidermal growth factor levels in saliva and the severity of oral mucositis during oropharyngeal radiation therapy. Cancer 89:2258-2265, 2000
13. Potten C: Protection of the small intestinal clonogenic stem cells from radiation-induced damage by pretreatment with interleukin 11 also increases murine survival time. Stem Cells 14:452-459, 1996
14. Booth D, Haley J, Bruskin A, et al: Transforming growth factor b3 protects murine small intestinal crypt stem cells and animal survival after irradiation, possibly by reducing stem cell cycling. Int J Cancer 86:53-59, 2000
15. Wymenga A, van der Graaf W, Hofstra L, et al: Phase I study of transforming growth factor-beta3 mouthwashes for prevention of chemotherapy-induced mucositis. Clin Cancer Res 5:1363-1368, 1999
16. Foncuberta M, Cagnoni P, Brandts C, et al: Topical transforming growth factor-beta3 in the prevention or alleviation of chemotherapy-induced oral mucositis in patients with lymphomas or solid tumors. J Immunother 24:384-388, 2001
17. Dörr W, Spekl K, Farrell C: Amelioration of acute oral mucositis by keratinocyte growth factor: Fractionated irradiation. Int J Radiat Oncol Biol Phys 54:245-251, 2002
18. Spielberger R, Still P, Emmanouilides G, et al: Efficacy of recombinant human keratinocyte Growth factor (rHuKGF) in reducing mucositis in patients with hematologic malignancies undergoing peripheral progenitor cell transplantation (auto-PBPCT) after radiation-based conditioning - Results of a phase 2 trial. Proc ASCO 20:7a, 2001 (abstr)
19. Kaplan G, Walsh G, Guido L, et al: Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing. J Exp Med Sci 175:1717-1728, 1992
20. Nemunaitis J, Rosenfeld C, Ash R, et al: Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant 15:949-954, 1995
21. Makkonen T, Minn H, Jekunen A, et al: Granulocyte macrophage-colony stimulating Factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: A prospective randomized study. Int J Radiat Oncol Biol Phys 46:525-534, 2000
22. Nicolatou O, Sotiropoulou-Lontou A, Skarlatos J, et al: A pilot study of the effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients during x-radiation therapy: A preliminary report. Int J Radiat Oncol Biol Phys 42:551-556, 1998
23. Rovirosa A, Ferre J, Biete A: Granulocyte macrophagecolony-stimulating Factor mouthwashes heal oral ulcers during head and neck radiotherapy. Int J Radiat Oncol Biol Phys 41:747-754, 1998
24. Sprinzl G, Galvan O, De Vries A, et al: Local application of granulocyte-macrophage stimulating factor (GM-CSF) for the treatment of oral mucositis. Eur J Cancer 37:2003-2009, 2001
25. Sironi MK, Pozzi P, Polentarutti N, et al: Inhibition of inflammatory cytokine production and protection against endotoxin toxicity by benzydamine. Cytokine 8:710-716, 1996
26. Epstein JB, Silverman S Jr, Paggiarino DA, et al: Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: Results from a multicenter, randomized double-blind, placebo-controlled clinical trial. Cancer 92:875-885, 2001
27. Hanson W, Marks J, Reddy S, et al: Protection from radiation-induced oral mucositis by a mouth rinse containing the prostaglandin E1 analog, misoprostol: A placebo controlled double blind clinical trial. Adv Exp Med Biol 400B:811-818, 1997
28. Porteder H, Rausch E, Kment G, et al: Local prostaglandin E2 in patients with oral malignancies undergoing chemo- and radiotherapy. J Craniomaxillofac Surg 16:371-374, 1988
29. Labar B, Mrsic M, Pavletic Z, et al: Prostaglandin E2 for prophylaxis of oral mucositis following BMT. Bone Marrow Transplant 11:379-382, 1993
30. Dueñas-Gonzalez A, Sobrevilla-Calvo P, Frias-Mendivil M, et al. Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: A randomized double-blind study. Bone Marrow Transplant 17:809-812, 1996
31. Foote R, Loprinzi C, Frank A, et al: Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis. J Clin Oncol 12:2630-2633, 1994
32. Okuno SH, Foote RL, Loprinzi CL, et al: A randomized trial of a nonabsorbable antibiotic lozenge given to alleviate radiation-induced mucositis. Cancer 79:2193-2199, 1997
33. Symonds RP, McIlroy P, Khorrami J, et al: The reduction of radiation mucositis by selective decontamination antibiotic pastilles: A placebo-controlled double-blind trial. Br J Cancer 74:312-317, 1974
34. Wijers OB, Levendag PC, Harms ER, et al: Mucositis reduction by selective elimination of oral flora in irradiated cancers of the head and neck: A placebo-controlled double-blind randomized study. Int J Radiat Oncol Biol Phys 50:343-352, 2001
35. Trotti A, Garden A, Warde P, et al: Phase III trial of iseganan HCl oral solution (iseganan) for reducing oral mucositis severity in patients receiving radiotherapy for head and neck malignancies (PROMPT-RT). Proc ASCO 21:228a, 2002 (abstr)
36. Bensadoun RJ, Franquin JC, Ciais G, et al: Low-energy He/Ne laser in the prevention of radiation-induced mucositis. A multicenter phase III randomized study in patients with head and neck cancer. Support Care Cancer 7:244-252, 1999
37. Peterman A, Cella D, Glandon G, et al: Mucositis in head and neck cancer: Economic and quality-of-life outcomes. J Natl Cancer Inst Monogr 29:45-51, 2001